021-51111890
购物车（）
sales@molnova.cn
BAY 2666605
CAS No. 2275774-60-0
BAY 2666605 ( —— )
产品货号. M28912 CAS No. 2275774-60-0
BAY 2666605 是一种口服活性的 PDE3A 和 PDE3B 抑制剂，IC50 分别为 87 nM 和 50 nM。 BAY 2666605具有抗癌作用。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥2356 | 有现货 |
|
| 10MG | ￥3772 | 有现货 |
|
| 25MG | ￥5933 | 有现货 |
|
| 50MG | ￥7989 | 有现货 |
|
| 100MG | ￥10440 | 有现货 |
|
| 200MG | ￥14040 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥1824 | 有现货 |
|
生物学信息
-
产品名称BAY 2666605
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述BAY 2666605 是一种口服活性的 PDE3A 和 PDE3B 抑制剂，IC50 分别为 87 nM 和 50 nM。 BAY 2666605具有抗癌作用。
-
产品描述BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.(In Vitro):BAY 2666605 inhibits brain cancer(glioma, more specifically glioblastoma, astrocytoma), breast cancer (ductal carcinoma and adenocarcinoma), cervical cancer, AML(erythroleukemia), lung cancer(NSCLC adenocarcinoma and SCLC), skin cancer(melanoma), esophagus cancer (squamous cell carcinoma), ovarian cancer, (teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer.(In Vivo):In murine xenotransplantation models of human cancer, BAY 2666605 (5 mg/kg; p.o) exhibits anti-tumor efficacy.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Angiogenesis
-
靶点PDE
-
受体Wnt
-
研究领域——
-
适应症——
化学信息
-
CAS Number2275774-60-0
-
分子量352.28
-
分子式C17H12F4N2O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 250 mg/mL (709.66 mM)
-
SMILESC[C@@H]1OC(=O)NN=C1C1=CC=C(C2=CC=C(F)C=C2)C(=C1)C(F)(F)F
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Basu D, et al. Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther. 2014 Jun;13(6):1457-67.
